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Abstract
Recently, an unprecedented effort has been directed at understanding the interplay between
chronic inflammation and development of cancer, with the case of inflammatory bowel disease
(IBD)-associated colorectal cancer at the forefront of this research endeavor. The last decade has
been particularly fertile, with the discovery of numerous innovative paradigms linking various
inflammatory, proliferative, and innate and adaptive immune signaling pathways to the
development of colorectal cancer. Because of the preponderant role of the intestinal microbiota in
the initiation and progression of IBD, recent efforts have been directed at understanding the
relationship between bacteria and colorectal cancer. The microbiota and its collective genome, the
microbiome, form a diverse and complex ecological community that profoundly impacts intestinal
homeostasis and disease states. This review will discuss the differential influence of the
microbiota on the development of IBD-associated colorectal cancer and highlight the role of
innate immune sensor-dependent as well as -independent mechanisms in this pathology.
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A significant risk of morbidity experienced by patients with inflammatory bowel disease
(IBD) is the development of colitis-associated colorectal cancer. The risk of developing
colitis-associated colorectal cancer increases with the duration and severity of inflammation
and may confer a 10-fold greater risk than that observed in the healthy population. Thus,
understanding the etiology of IBD represents a key step in elucidating the events leading to
colitis-associated colorectal cancer and the elaboration of strategies aimed at preventing the
pathology.
Genome-wide association studies and experimental models of IBD underscore the
importance of the innate immune system and the intestinal microbiota in the pathogenesis of
IBD.1-6 Numerous innate immune sensors and their associated signaling proteins have been
linked to the maintenance of intestinal homeostasis through their effects on cellular
proliferation, inflammation, and wound healing. An emerging body of literature highlights
the impact of these innate immune sensors in protecting or promoting the development of
colitis-associated colorectal cancer and much of the focus lies in the role of the complex
intestinal microbiota. Indeed, the human gastrointestinal tract is colonized by thousands of
bacterial species, amounting to more than 100 trillion bacteria. This complex microbial
community carries a rich and diverse microbial genome, the microbiome, with a tremendous
metabolic potential that influences intestinal homeostasis. Recent reports indicate that
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microbial composition may impact the status of various pathologic conditions including IBD
and colorectal cancer. In this review we will focus on the relationship between innate
sensors, the microbiota and development of colitis-associated colorectal cancer.
MICROBIAL SYMBIONTS OF THE MAMMALIAN INTESTINE
The human intestinal microbiota is a community of 1013 − 1014 microorganisms that reside
in the intestine and normally participate in a symbiotic relationship with their eukaryotic
host.7-9 While IBD has been recognized as a disease influenced by the intestinal microbiota,
difficulty in culturing these complex microorganisms has precluded the formal identification
of colitogenic bacteria. Moreover, IBD is likely not caused by a single microbial entity but
rather through the action of a complex consortium of microorganisms that render
identification of these bacteria even more challenging using classical microbiology culturing
techniques. However, characterization of this complex ecological system has made an
extensive leap forward through the use of newly developed molecular approaches focused
on differentiating specific genetic signatures in ribosomal 16S genes.10,11 Unbiased
metagenomics sequencing has revealed that the human distal intestinal microbiota comprises
two predominant phyla, the Firmicutes and Bacteroidetes, with lesser contributions from
Proteobacteria and Actinobacteria, and minor contributions from Fusobacteria,
Verrucomicrobia, and Cyanobacteria.12,13 Importantly, the murine microbiota is remarkably
similar14; thus studies performed in murine models will likely have translational
implications relevant to human disease.
The microbiome contains a wealth of information, encompassing 150-fold as many genes as
the human genome.15,16 Accordingly, a considerable worldwide effort is under way to
identify both the constituents and unique traits of this complex microbial community. One
such endeavor is the International Human Microbiome Consortium, which includes the
Human Microbiome Project and the Metagenomics of the Human Intestinal Tract project
(MetaHIT).17,18 A primary goal of these projects is to determine the presence, composition,
and function of a putative core microbiome shared among all humans. Already these studies
have hinted that a core human microbiome exists at the gene level, with a large number of
microbial genes and pathways shared among individuals.13,18 Deviations from this core
microbiome could potentially affect human health and promote disease. Thus, characterizing
the vast intestinal microbial community present in healthy as well as pathologic conditions
will likely revolutionize our conception of bacteria/host interactions and identify new
physiological processes influenced by the microbiota. Already the microbiota has been
linked to cardiac development,19 angiogenesis,20 innate and adaptive immunity,21-24
metabolism,25 nutrient acquisition,26 and gastrointestinal development and homeostasis.27
Furthermore, alterations in the microbial community are associated with multiple diseases,
including obesity,13,14,28-30 fatty liver disease,31 type 1 and type 2 diabetes,32,33 kidney
disease,34 arthritis,35 IBD,16,36 and colorectal cancer.37 In IBD, analyses of the fecal and
mucosally adherent microbiota have revealed significant differences in microbial
community structure between patients and healthy controls. For example, studies have
consistently identified reductions in total gut microbial concentration, decreases in the
richness and diversity of the microbiota, and changes in the proportion of the two dominant
phyla, the Firmicutes and Bacteroidetes.16,38-40 At the moment, though, the relationship
between alterations in the microbiota and development of IBD and colorectal cancer is
unclear.
MICROBIOTA CAN CONFER HOST TRAITS
The major limitation of total microbial gene pool analysis in health and disease, through
what is known as metagenomic studies, relates to the correlative nature of this experimental
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approach. In essence, do changes in the microbial composition and metagenome directly
influence the development of disease? The ability to transfer host traits through microbiota
transplants suggests that a dysbiotic microbial community plays an active, rather than
passive role in disease process. Glimcher and colleagues41 have described a transferable trait
in colitis-prone TRUC mice (Tbx21−/−; Rag2−/− ulcerative colitis). TRUC mice develop
highly penetrable colitis that progresses to colorectal cancer.42 Housing either newborn or
adult wildtype (WT) mice with TRUC mice induces aggressive colitis in this normally
colitis-resistant strain.41 Although microbiome analyses were not performed in these mice,
these observations suggest that the colitis phenotype is transferred through a dysbiotic
microbiota present in TRUC mice. Analysis of the TRUC microbiome and microbiota
transplants into germ-free mice may address this question and provide further insight into
the transmissibility of such traits.
The impact of the microbial community on host traits is not limited to an intestinal
phenotype. For example, obesity alters the composition of the gut microbiota and increases
its metabolic potential to harvest energy from the host diet.13,14,28-30 Microbiota
transplantation from obese mice into lean germ-free recipients induces weight gain and
increases adiposity, demonstrating that these traits can be conferred through a microbial
dependent mechanism.29,30 More recently, Tlr5-deficient mice were observed to become
hyperphagic and develop metabolic syndrome comprising hyperlipidemia, hypertension,
insulin resistance, and enhanced adiposity.43 In these mice, specific bacterial phylotypes
were expanded and contracted compared to WT mice. Interestingly, hyperphagia and
metabolic syndrome are transferable to WT mice upon fecal transplantation of microbiota
obtained from Tlr5−/− mice.43 These fascinating experiments demonstrate that the
microbiota has the potential to profoundly impact the host health status.
HOST RECOGNITION OF MICROBIAL SPECIES AFFECTS COLITIS AND
COLORECTAL CANCER
Germ-free studies have revealed a key role for the microbiota in driving colorectal cancer.
Hereditary colorectal cancer is commonly modeled with the ApcMin/+ (multiple intestinal
neoplasia allele of the adenomatous polyposis coli gene) mouse, a model of human familial
adenomatous polyposis. When raised in conventional or specific pathogen-free (SPF)
conditions, a mutation in the tumor suppressor Apc causes this mouse strain to develop tens
to hundreds of intestinal adenomas.44,45 However, mice raised in germ-free conditions
exhibit ≈50% reduction in intestinal tumors compared to those housed in SPF conditions.46
More recently, the microbial composition has been found to influence the development of
colitis-associated colorectal cancer. In the newly developed AOM/IL-10−/− model, intestinal
inflammation occurs spontaneously from lack of immunosuppressive IL-10, and
tumorigenesis is initiated with the colon-specific carcinogen azoxymethane (AOM).47 When
raised in conventional or SPF conditions, these mice develop extensive intestinal
inflammation and colonic adenomas. However, when mono-associated with Bacteroides
vulgatus these mice exhibit fewer tumors. Remarkably, mice raised in germ-free conditions
are devoid of intestinal inflammation and tumors.47 These findings highlight the critical role
of specific members of the commensal microbiota in the development of colitis-associated
colorectal cancer.47
Although the microbiota influences the development of colorectal cancer, colitis-associated
colorectal cancer, and other forms of cancer (Table 1),48-97 the extent of host microbial
recognition in this process is still unclear. Humans, mice, and other eukaryotes are equipped
with an elegant repertoire of receptors, and each recognize specific conserved microbial
patterns, such as components of bacterial cell walls or nucleic acids. These microbial sensors
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are termed pattern recognition receptors (PRR) and include retinoic acid inducible gene-I
like RNA helicases (RLH), C-type lectin receptors (CLR), nucleotide-binding domain
leucine-rich repeat proteins (NLR; also known as Nod-like receptors), and Toll-like
receptors (TLR).98-101 Many of these receptors are expressed on intestinal epithelial cells
(IEC) as well as on various mucosal immune cells. Upon engagement, these receptors
initiate signaling cascades that activate numerous downstream effector systems including
mitogen-activated protein kinases (MAPK), nuclear factor of kappa B (NF-κB), and
interferon regulatory factors (IRFs) that then modulate apoptosis, proliferation, cell
migration, and inflammation.102,103
The most well-characterized family of PRRs is the TLRs. With the exception of TLR3, these
extracellular or endosomal PRRs signal through the adaptor protein myeloid differentiation
factor 88 (MyD88).104,105 Accordingly, investigators have utilized Myd88−/− mice to link
host innate signaling with the microbiota and development of colitis-associated colorectal
cancer. Development of colitis and colorectal cancer is strongly reduced in Il10−/− mice
deficient in MyD88 signaling.1,47,106 Importantly, deletion of Myd88 also diminishes
development of spontaneous colorectal cancer in ApcMin/+ mice, reducing both intestinal
tumor size and multiplicity.107 The cellular compartment responsible for MyD88-dependent
proinflammatory and procarcinogenic signaling is not completely understood. However,
MyD88 signaling in macrophages promotes colonic epithelial progenitor cell proliferation
and cellular organization within colonic crypts,108,109 raising the possibility that disrupted
MyD88 signaling may affect the balance between proliferation and apoptosis. Indeed, bone
marrow transplant experiments in Tlr4−/− mice indicate that immune cells are critical in
promoting the development of colitis-associated colorectal cancer.110,111 These data suggest
that host recognition of microbial species is necessary for the development of colitis-
associated colon cancer.112-115
Because host PRRs distinguish between a wide spectrum of microorganisms, it is important
to establish their individual contribution to the development of colitis and colorectal cancer.
Like TLR4,116 PRRs of the NLR family including NOD1, NOD2, and NLRP3 have been
genetically linked to the development of IBD.112-115 However, in contrast to TLR4/MyD88,
these intracellular sensors appear to play a protective role in gastrointestinal disease.117,118
Interestingly, Nod2-deficient mice harbored increased numbers of gut commensal bacteria
and impaired bacterial killing and antimicrobial peptide secretion in the intestine,119
providing a potential mechanism by which Nod2 mutations may perturb intestinal
homeostasis. Recent findings indicate a link between Nod2 polymorphisms and
development of colorectal cancer.120,121 However, the lack of data generated from
experimental models of colorectal cancer and colitis-associated colorectal cancer precludes a
direct assessment of the function of NOD2 in the carcinogenic processes.
Similarly, NOD1, a close relative of NOD2, has been shown recently to play a protective
role against development of colitis and colorectal cancer. Compared to WT mice, Nod1-
deficient mice displayed exacerbated colitis in response to dextran sulfate sodium (DSS)
exposure.122 Likewise, AOM/DSS-induced colitis-associated colorectal cancer and
spontaneous colorectal cancer (ApcMin/+) is augmented in Nod1−/− mice, a phenomenon
attenuated with broad-spectrum antibiotic treatment.122 These findings suggest a role for
NOD1 and microbial signaling in the development of colorectal cancer. Furthermore, the
related intracellular sensor NLRP3 also appears protective against colitis and colitis-
associated colorectal cancer, a role attributed to its expression in immune cells.123 These
findings suggest a protective role for NLRP3, NOD1, and microbial signaling in the
development of colorectal cancer. The fact that TLR/MyD88 signaling promotes the
development of colorectal cancer, whereas NLR signaling appears to prevent this pathology,
highlights the complex interaction between the host and the microbiota. These differential
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responses may be dictated by the bacterial motif recognized by a particular PRR and/or the
location of the PRR, i.e., intracellular versus extracellular. Since NOD1, NOD2, and NLRP3
reside in an intracellular location, perhaps bacterial invasion activates these microbial
sensors, which then initiate a protective response to clear invading bacteria and restore
intestinal homeostasis.
Although the above studies clearly indicate the importance of PRRs in modulating the
development of colitis-associated colorectal cancer, the interplay between inflammation and
colorectal cancer is not always clear. For example, development of colitis-associated
colorectal is strongly reduced in AOM/DSS-treated Tlr4−/− mice compared to WT mice,
whereas the inflammatory status is marginally affected in these mice.110 This incomplete
relationship between inflammatory status and tumorigenesis is also observed in AOM/DSS-
treated Il6−/− and Stat3IEC−/− mice.124 The IL-6/STAT3 signaling axis profoundly
modulates intestinal homeostasis through pro-proliferative and antiapoptotic effects.
Remarkably, while AOM/DSS-exposed Il6−/− or Stat3IEC−/− mice display increased
intestinal inflammation and proinflammatory cytokine secretion, they exhibit significantly
fewer intestinal tumors than WT mice. In addition, Enterococcus faecalis mono-associated
Il10−/− mice develop inflammation to the same extent as conventionalized Il10−/− mice;
however, tumors fail to develop in the mono-associated mice.125 These observations suggest
that mechanisms other than inflammation can influence the development of colorectal
cancer. Although this concept is at odds with epidemiologic data in humans showing a
correlation between inflammatory status and colorectal cancer,126 an intriguing possibility is
that microbial status could impact tumorigenesis without directly affecting the inflammatory
status (Fig. 1). Indeed, up to 80% of patients with long-standing IBD (<30 years) do not
develop colitis-associated colorectal cancer,127 suggesting that inflammation alone is not
sufficient to promote colorectal cancer.
MICROBIAL INFLUENCE ON CARCINOGENESIS
The impact of microorganisms on the development of colorectal cancer has been mostly
studied from the point of view of PRR signaling and inflammatory responses. However, it
has become apparent that the tremendous metabolic capacity offered by the microbiota
(referred to as the metabolome) likely plays an important role during the carcinogenesis
process, independently of overt inflammation (Table 2).
The activation or detoxification of carcinogens that modulate the tumorigenic process is
strongly influenced by the abundant enzymatic activities contributed by the intestinal
microbiota.128-168 In the 1960s it was observed that germ-free rats did not develop intestinal
tumors from exposure to the carcinogenic plant glycoside cyasin. However, intestinal tumors
developed in germ-free rats directly administered methylazoxymethanol, the downstream
active metabolite of cyasin.169 The generation of this metabolite is dependent on bacterial β-
glucosidase enzyme activities,169 strongly implying that the microbiota influences the
production of bioactive carcinogenic compounds. Further investigation has revealed that the
intestinal microbiota can convert latent carcinogens into bioactive forms through the action
of various enzymes such as β-glucuronidase, β-glucosidase, azoreductase, and
nitroreductase.170 The most commonly used experimental colon carcinogen, AOM, is first
hydrolyzed in the liver to methylazoxymethanol and conjugated with glucuronic acid before
transport to the intestine through bile secretion.171 Further metabolism through bacterial β-
glucuronidase converts the glucuronic acid-conjugated methylazoxymethanol to its
carcinogenic form that spontaneously yields the highly reactive methyl carbonium
ion.170,172,173 Interestingly, β-glucuronidase inhibition significantly reduces the ability of
AOM to induce tumors in rats.149 In addition, the heterocyclic amines 2-amino-3-
methylimidazo-[4,5-f]quinoline (IQ), 2-amino-3,8-dimethylimidazo-[4,5-f]quinoxaline
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(MeIQx), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) that form when
meat is cooked to high temperatures must be metabolically activated by the enzymatic
activities of intestinal microbes to exert full mutagenic potential.150,174-177 These important
observations have a profound implication for the field of colorectal cancer research since
animal facilities at various institutions and even commercial vendors likely harbor different
microbial communities.178 Presumably, their microbiota contain differential metabolic
capacities that could influence their responses to procarcinogenic agents such as AOM.
Likewise, phenotypic variability observed in Il10−/− and Smad3−/− mice appears to correlate
with the presence of specific opportunistic microorganisms such as Helicobacter sp. and
Citrobacter sp.179-182
Interestingly, probiotic bacteria such as Lactobacillus sp. and Bifidobacterium sp. exert
anticarcinogenic effects, in part by inactivating microbial enzymes important for
procarcinogen activation.183 For example, probiotic lactic acid bacteria including L. casei
and L. acidophilus can decrease the activity of β-glucuronidase, azoreductase, and
nitroreductase.184,185 In fact, B. longum reduces AOM-induced aberrant crypt formation,
which correlates with a decrease in AOM-activating β-glucuronidase activity.186 In addition,
other Lactobacillus sp. and Bifidobacterium sp. can inhibit DNA damage and tumorigenesis
induced by N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), 1,2-dimethylhydrazine
(DMH), AOM, and heterocyclic amines IQ, MeIQx, and PhIP,187-191 although the extent to
which inactivation of carcinogen-activating enzymes is involved in these processes remains
unknown. This balance of activation and detoxification is reminiscent of the balance
between host oncogenes and tumor suppressors and suggests that microbial community
structure and its associated metabolomic capacity play a significant role in the initiating step
of carcinogenesis (Fig. 1).
DNA damage and chromosomal instability are early genetic events involved in the
development of colorectal cancer. Chromosomal instability, such as aneuploidy, is
associated with long-standing IBD and frequently predicts the future development of
colorectal cancer.192-194 A common commensal intestinal bacterium, E. faecalis, induces
aneuploidy in colonic epithelial cells and aggressive colitis in mono-associated Il10−/−
mice.161,195,196 Inhibitors of reactive oxygen and nitrogen species (RONS) prevent E.
faecalis-induced aneuploidy,161,197 suggesting that the unique ability of this bacterium to
induce RONS can lead to chromosomal instability in a susceptible host. Experimentation in
mice deficient in the antioxidant enzymes glutathione peroxidase -1 and -2 (Gpx1/2−/−)
further supports the role of the microbiota and RONS in carcinogenesis. Gpx1/2−/− mice
spontaneously develop intestinal tumors with ≈25% penetrance when raised in conventional
conditions, whereas this is reduced to <9% in SPF conditions and abolished in germ-free
animals.198 These findings strongly indicate that the microbiota—and most likely specific
members of the microbiota—induce RONS that promote carcinogenesis.
The protective role for the microbiota in intestinal homeostasis includes their ability to
influence epithelial cell proliferation and apoptosis. A major mechanism by which this is
accomplished involves microbial fermentation of dietary fibers to the short chain fatty acids
(SCFA) acetate, propionate, and butyrate. These SCFAs, butyrate in particular, are avidly
absorbed by colonocytes and used as a primary source of energy. In addition to their
important antiinflammatory role,199,200 SCFAs support intestinal homeostasis and the
resolution of intestinal injury by promoting cellular proliferation and differentiation in the
normal nonneoplastic colon.200,201 Remarkably, SCFAs exert an opposite effect on
cancerous cells. Butyrate in particular can induce apoptosis in colon cancer cell lines by a
variety of mechanisms, most of which are associated with its role as a histone deacetylase
inhibitor. This can involve hyperactivation of Wnt, sensitization to Fas-mediated apoptosis,
and activation of the intrinsic/mitochondrial apoptosis pathway through upregulation of Bak,
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downregulation of Bcl-xL, cytochrome-c release, and caspase-9 activation.202-207
Nonetheless, butyrate may only provide protection during the early stages of tumorigenesis,
as the two major receptors for butyrate, SLC5A8 and GPR109A, are frequently silenced in
human cancers.208-211
Although colorectal cancer has not been linked to any specific microorganisms, some
species have been identified as cancer-promoting bacteria (Table 1). For example,
Helicobacter pylori infection in humans predisposes to gastric cancer.212 In addition, H.
hepaticus augments both experimental colitis-associated colon cancer and spontaneous
colorectal cancer in mice.179,213 Bacteroides fragilis is a common intestinal commensal, yet
an enterotoxigenic variant induces spontaneous colonic tumorigenesis in ApcMin/+ mice.60
Therefore, exclusion of opportunistic pathogens by commensal bacteria may represent a
natural defense against gastrointestinal diseases, including colorectal cancer. This is
exemplified in the therapeutic use of probiotics, live bacteria that confer health benefits to
the host. Probiotic bacteria engage the host to produce biofilms that prevent adhesion or
invasion of pathogenic species, maintain gut barrier function by preventing redistribution of
host tight junction proteins, induce host cytokines to modulate inflammation an immunity,
and neutralize carcinogens and toxins.214-219 Commensal bacteria may also exert selective
pressure against potential intruders as a mechanism to maintain a niche. For example,
conditioned medium derived from a human intestinal microbiota directly inhibits synthesis
of an enterohemorrhagic E. coli O157:H7 toxin.220 Communication with the commensal
microbiota provokes antimicrobial responses from the host epithelium including the release
of antibacterial lectins like RegIIIc, angiogenins, and α-defensins.221-223 Remarkably, these
antibacterial products not only deplete subsets of potentially pathogenic bacteria, but also
protect against subsequent aberrant immune responses. For example, the intestinal
microbiota of mice expressing a human enteric α-defensin, DEFA5, is depleted of
segmented filamentous bacteria.222 Intriguingly, this class of bacteria induces IL-17-
producing T-helper (Th17) cells, which have been strongly linked to IBD and colorectal
cancer.60,178,222,224,225 In fact, B. fragilis enterotoxin promotes colorectal carcinogenesis
through IL-17,60 and B. fragilis prostate-specific antigen (PSA) exerts protection by
suppressing Th17 differentiation.226
These numerous reports highlight the critical role of the intestinal microbiota in shaping
intestinal health. Members of this microbial community can modulate immune and
inflammatory responses, activate and detoxify carcinogens, promote DNA damage and
chromosomal instability, shift the balance of proliferation and apoptosis, and thwart
pathogen invasion.
FACTORS INFLUENCING MICROBIAL COMMUNITY STRUCTURE
The intestinal microbiota is a dynamic community strongly influenced by external forces
including genetic factors, inflammation and infection, antibiotic treatment, and
diet.16,29,30,227-231 Metagenomics studies have indicated greater similarity between the
intestinal microbiota of family members versus unrelated individuals.14,229 Yet analyses of
congenic mice bred from heterozygotes and raised in the same cage have revealed that
deficiency of even one host gene can significantly change intestinal microbial community
composition. For example, deficiency of the Crohn’s disease-associated Nod2 gene
increases the total number of commensal bacteria and reduces the ability of these mice to
clear H. hepaticus.119 NOD1-deficient mice harbor an increased total number of commensal
bacteria, yet a decreased number of protective Lactobacillus species.232 MyD88-deficient
NOD diabetic mice exhibit microbiota changes at the family level and in the proportion of
the two prominent phyla, the Firmicutes and Bacteroidetes. Furthermore, deficiency of
MyD88 allows bacterial penetration of the intestinal epithelial barrier and systemic
Arthur and Jobin Page 7













dissemination.233,234 Taken together, these data suggest that host innate signaling influences
the microbial community structure, which in turn shapes intestinal homeostasis.
Alterations in microbial community structure occur rapidly upon changes in dietary
habits.29,30,235,236 Gordon and colleagues found that the intestinal microbial community
structure of mice maintained on standard low-fat chow could be changed significantly
within weeks of switching to a high-fat diet (HFD). Consumption of HFD was associated
with a shift in the balance of the two dominant phyla, the Bacteroidetes and Firmicutes.29,30
In fact, the most prominent change was an expansion in one group of Firmicutes, the
Mollicutes, which again contracted when mice were switched back to standard low-fat
chow. The Mollicutes expansion was associated with an increased ability for energy harvest,
and this trait could be transferred by microbiota transplant into lean recipients.29,30
Importantly, similar changes in the proportion of Firmicutes and Bacteroidetes have been
identified in overweight and obese humans, genetically obese mice, and obesity-resistant
mice fed HFD diet.13,14,28-30 As human colorectal cancer is tightly linked to diet,237,238 it
will be interesting to see if diet-induced changes in the microbiota also influence the
development of colorectal cancer.
CONCLUSIONS AND FUTURE DIRECTIONS
The events leading to the development of colorectal cancer are complex. Adding to the
complexity of the disease is the growing evidence that the microbiota and its associated
microbiome are active participants in the pathology. Within recent years, we have
experienced exponential growth in our understanding of how the microbiota affects
intestinal health and diseases. Gastrointestinal diseases including esophagitis/Barrett’s
esophagus, gastric cancer, IBD, and colorectal cancer have been strongly linked to
alterations in the composition of the gut microbiota.16,37,47,212,239 Although tantalizing,
these observations have not moved beyond the descriptive phase and into functional and
malleable territory. Consequently, numerous questions remain unanswered.
The most pressing question is if the shift in the microbiota directly alters the course of
disease. Functional studies using dysbiotic microbiota obtained from germ-free animals and
various disease states—inflammation, colorectal cancer, etc.—will help address this
important question.
Another key question relates to the identity of the microorganisms promoting health and/or
disease. Continuous progress in next-generation gene sequencing technology and more
affordable cost associated with this high-throughput technique will likely yield important
information regarding the composition of healthy and dysbiotic microbiota. This information
may be sufficient to initiate functional experiments where a cause/effect relationship could
be established using animal models. The fact that a “core microbiome” was recently
identified in healthy individuals and that deviation from this core is associated with IBD16-18
indicate that a potential dysbiotic microbiota could be found in colorectal cancer patients
and tested in experimental models.
Although identification of microbial consortia associated with particular pathological
conditions represents an important milestone, this critical step is not sufficient to fully
comprehend the role of the microbiota in health and disease. Indeed, the in-depth
characterization of the metabolic capacity contributed by the microbiota in relation to the
maintenance of intestinal homeostasis and development of disease states is undeniably a
central piece of the metagenomic puzzle. With this knowledge will come the possibility to
manipulate the human microbiota and its metabolic capacity as an innovative approach to
treating and preventing IBD and colorectal cancer.
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In summary, the microbiota can no longer be considered a bystander in the complex
biological events regulating intestinal homeostasis. Both the composition of the microbiota
and its associated metabolic capacity likely influence host susceptibility to developing
various pathological conditions, including IBD and colorectal cancer (Fig. 2). Harnessing
the power of the microbiota holds tremendous promise in medicine and could represent a
novel means to alleviate these devastating diseases.
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The intestinal microbiota promotes inflammation and neoplasia in the colon. Conserved
microbial signatures are recognized by pattern recognition receptors such as TLRs, which
trigger downstream signaling pathways leading to the expression of various genes including
growth factors and inflammatory mediators. Autocrine and paracrine signaling from these
mediators amplifies inflammation and promotes neoplasia. Independent of inflammation,
microbial enzymes of the metabolome process latent dietary procarcinogens to their
biologically active form and elicit neoplastic changes.
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Microbial dysbiosis is associated with a variety of diseases including IBD and colorectal
cancer. In a healthy individual a balanced microbial community structure promotes the
maintenance of intestinal homeostasis. The presence of a dysbiotic microbiota that is
associated with loss of protective species and predominance of adherent/invasive species
promotes inflammation, activation of innate and adaptive immunity, and loss of barrier
function in a susceptible host. Longstanding IBD and persistence of microbial dysbiosis may
encourage genetic changes, loss of cell cycle control, and immune dysfunction that promote
neoplastic changes and development of colorectal cancer.
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